Confirming an integrated pathology of diabetes and its complications by molecular biomarker-target network analysis

Abstract

Despite ongoing research into diabetes and its complications, the underlying molecular associations remain to be elucidated. The systematic identification of molecular interactions in associated diseases may be approached using a network analysis strategy. The biomarker-target interrelated molecules associated with diabetes and its complications were identified via the Comparative Toxicogenomics Database (CTD); the Search Tool for Recurring Instances of Neighboring Genes was utilized for network construction. Functional enrichment analysis was performed with Database for Annotation, Visualization and Integrated Discovery software to investigate connections between diabetes and its complications. A total of 142 (including 122 biomarkers, 10 therapeutic targets and 10 overlapping molecules) biomarker-target interrelated molecules associated with diabetes and its complications were identified via the CTD database, and analysis of the network yielded 1,087 biological processes and fifteen Kyoto Encyclopedia of Genes and Genomes pathways with significant P‑values. Various critical aspects of the networks were examined in the present study: a) Intermolecular horizontal and vertical combinations in biomarkers and therapeutic targets associated with diabetes and its complicationb) network topology properties associated with molecular pathological responsec) contribution of key molecules to integrated regulation; and d) crosstalk between multiple pathways. Based on a multi-dimensional analysis, it was concluded that the integrated molecular pathological development of diabetes and its complications does not proceed randomly, which suggests a requirement for integrated, multi-target intervention.

Network Pharmacology-Based Investigation and Experimental Exploration of the Antiapoptotic Mechanism of Colchicine on Myocardial Ischemia Reperfusion Injury

“…Therefore, finding a resultful drug to treat MIRI makes sense ( Bellis et al, 2020 ). Network pharmacology is an emerging discipline based on systems biology, which is used to analyze biological system networks to select specific signal nodes, so that the potential interaction between drugs and targets can be accurately determined ( Barabasi et al, 2011 ; Zhao et al, 2016 ). For these reasons, there is no doubt that network pharmacology is one of the efficacious strategies for discovering new drugs ( Hopkins, 2008 ).…”

Different network pharmacology mechanisms of Danshen-based Fangjis in the treatment of stable angina

“…Network pharmacology is a new discipline based on systems biology that is used to analyze biological systems networks to select specific signal nodes to enable the design of multi-target molecular drugs. Network pharmacology emphasizes the multi-faceted regulation of signaling pathways to improve the therapeutic effects of drugs and reduce their side effects, thus improving the success rate of clinical trials of new drugs and reducing the cost of drug research and development, and is a more appropriate method when using complex networks to analyze the mechanism of multi-target drugs [52][53][54] . This approach is comparable to the multi-component and multi-target ideas characterizing traditional Chinese medicine; and in this study, these two methodologies -network meta-analysis and network pharmacology -were combined.…”